Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619589 · ClinicalTrials.gov registry record
Characterization of Dyschromic Hypertrophic Scar
A clinical trial of Hypertrophic Scar and Hyperpigmentation, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04619589: Completed study of Hypertrophic Scar and Hyperpigmentation, sponsored by Medstar Health Research Institute.
NCT04619589 is a study of Hypertrophic Scar and Hyperpigmentation that has completed, run by Medstar Health Research Institute. The registered enrollment target is 50 participants, above the 37-participant average among 7 other Hypertrophic Scar trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04619589, a study of Hypertrophic Scar and Hyperpigmentation, has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust pigment. These techniques involve the creation of a donor site and do not utilize the cells that may already be present in scars. This study aims to confirm melanocyte presence in regions of hypo- and hyper- pigmented HTS. If melanocytes can be found in regions of hypopigmentation, these scars may be able to be treated in the future by pigmentation stimulators without the need for surgery. Additionally, if pigmentation specific molecules of interest can be found to be up-regulated in hyperpigmented scar, these may be able to be altered by a pharmacotherapy.
Primary Outcome
Confirm melanocyte presence in regions of hyper- and hypo-pigmented HTS, as well as normal skin by multiple assays including en face staining and immunofluorescent staining with melanocytes markers.
Conditions Studied
Study Locations (1)
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2023-06-28 |
What the finished NCT04619589 record still lists
NCT04619589 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, above the 37-participant average among 7 other Hypertrophic Scar trials with a reported enrollment target (35% higher).
The record links to 4 conditions, with Hypertrophic Scar appearing as the primary indexed condition, and to 0 interventions.
NCT04619589 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04619589 about?
NCT04619589 is a clinical study titled "Characterization of Dyschromic Hypertrophic Scar". Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust pigment. These techniques involve the creation of a donor site and do not ut...
What is the current status of trial NCT04619589?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2019-05-21. Estimated completion is 2023-06-28.
What conditions does trial NCT04619589 study?
This clinical trial studies the following conditions: Hypertrophic Scar, Hyperpigmentation, Burn Scar, Hypopigmented Scar.
Who is sponsoring clinical trial NCT04619589?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04619589 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Scar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
RECRUITING · NA
-
Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
COMPLETED · Phase 2
-
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
COMPLETED · NA
-
Effects of Pulsed Dye and CO2 Laser in Treatment of Hypertrophic Burn Scars.
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI